Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are over 18 years old, of any gender
- People who have pancreatic cancer (a specific type called PDAC) that has spread or is at an advanced stage
- People who have received no more than one previous chemotherapy treatment for their advanced or spread cancer (radiation therapy does not count as a previous treatment)
- People who have a stored tumor tissue sample available, taken during surgery or a biopsy from the original tumor and/or from a site where the cancer has spread, along with the associated pathology report
- People who are expected to live for more than 3 months
- People who have a performance status score of 0 or 1, meaning they are able to carry out normal daily activities with little or no difficulty (confirm with trial site)
Who may not be able to join:
- People for whom a treatment aimed at curing their cancer is available
- People who have a condition that makes blood sample collection unsafe or unsuitable
- People who have another cancer that is currently growing or requires active treatment — though some exceptions may apply, such as certain treated skin cancers or a specific type of treated cervical cancer (confirm with trial site)
- People whose personal, psychological, family, location, or social circumstances may make it difficult to give informed consent or follow the study procedures, as assessed by the trial doctor
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Philippe CASSIER, MD, PhD, Centre Leon Berard
Phone: 0426556833
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients with at least one actionable alteration defined as an alteration shown to predict for sensitivity to a drug FDA/EMA approved for use in another cancer type, or a relevant alteration for inclusion in a clinical trial.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.